**Memory Improvement Through Nicotine Dosing (The MIND Study)**

This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study sponsored by the National Institute of Health (NIH). The purpose of the study is to see if a daily nicotine skin patch can produce a significant cognitive, clinical, and functional improvement in older adults with mild cognitive impairment (MCI). Nicotinic receptors in the brain have been shown to play a critical role in memory function in earlier studies, with nicotine improving attention, learning, and memory function. The study will enroll 300 participants who will be randomly assigned (50:50) to receive either the transdermal nicotine patch, beginning at 3.5mg/day, and increasing to 21mg/day, or placebo patch.

**Category:** Alzheimer’s Disease Research

**Study Population:** Individuals with mild memory loss or current diagnosis of mild cognitive impairment (MCI)

**Study Length:** 26 months, with clinic visits taking place every 3 months

**Requirements:**

* Adults 55-90 years old
* Volunteers do not have to be previously diagnosed with mild cognitive impairment (MCI),but should have complaints of existing memory impairment/decline. Memory testing will be done to confirm eligibility prior to entry into the trial.
* Volunteers must not have used any tobacco products within the past year, such as smoking (cigarettes, pipes, cigars, etc.) or use of other nicotine products (chewing tobacco, e-cigarettes, nicotine patches, gum, sprays, etc.), and will not be able to use nicotine products during participation in the trial.
* A study partner (family member, close friend, caregiver) who has frequent contact with the patient and can accompany him/her to most study visits is required.
* Must sign an informed consent document indicating that he or she understands the purpose of the study, procedures required, and is willing to participate in the study.

**Benefits:**

If you are assigned to the group that receives the nicotine patch you may benefit from participating in this study, but that cannot be guaranteed. Participation in this study may help to improve your condition, but it is also possible that your condition may not improve or may worsen. Participants have the benefit of additional health monitoring and follow up beyond what may be available as standard of care. Your participation in this study may help us understand how nicotine affects cognition in individuals with memory loss and Alzheimer’s disease.

**Contact Information:**

Allison Acree, Lead Recruitment Coordinator – (843) 608-1950 xt.1109

Codi Cammer, Recruitment Coordinator – (843) 608-1950 xt.1110

Dr. Jacobo Mintzer, Principal Investigator – (843) 608-1950 xt.1101